CompletedNot Applicable

Clinicopathological Predictors of Recurrence in Papillary Thyroid Carcinoma

Italy1,113 participantsStarted 2000-01-07

Plain-language summary

The goal of this observational study is to identify demographic and clinicopathological factors associated with disease recurrence in adults with histologically confirmed papillary thyroid carcinoma (PTC) who achieved an initial disease-free status after primary treatment. The main questions it aims to answer are: Which demographic and clinicopathological characteristics are associated with an increased risk of PTC recurrence? Researchers will compare patients who developed biochemical or structural recurrence with those who remained recurrence-free to assess the prognostic role of age, sex, tumor size, histological subtype, vascular invasion, capsular invasion, gross invasion of the prethyroid strap muscles, concomitant thyroiditis, multifocality, lymph-node status, and pathological stage. As this is a retrospective study, participants will not undergo any study-specific intervention or additional procedure. Researchers will review existing demographic, surgical, pathological, treatment, and follow-up data from a prospectively maintained institutional database. Follow-up data include serial serum thyroglobulin measurements, neck ultrasonography, recurrence, and disease-specific mortality.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * histologically confirmed diagnosis of papillary thyroid carcinoma * no history of previous neck surgery * availability of complete clinical, pathological, treatment, and follow-up data; * achievement of an initial disease-free status after primary treatment * minimum follow-up of 60 months for patients who remained recurrence-free Exclusion Criteria: * histological diagnosis other than papillary thyroid carcinoma * previous neck surgery * incomplete clinical, pathological, treatment, or follow-up records * follow-up shorter than 60 months in patients without recurrence * biochemical or structural evidence of persistent disease after initial treatment

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Recurrence

Timeframe: From surgery to the end of follow-up (minimum of 60 months)

Trial details

NCT IDNCT07695974

SponsorUniversity of Roma La Sapienza

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-08-31

View on ClinicalTrials.gov More Papillary Thyroid Carcinoma trials